European Commission has approved two new indications for ramucirumab.

• Ramucirumab in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression after platinum-based chemotherapy.
• Ramucirumab in combination with FOLFIRI (irinotecan, folinic acid, and 5 fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.

“Lung and colorectal cancer are the two top leading causes of cancer deaths in the EU and, despite treatment advances, there continues to be a significant need for new second-line treatment options for people with these types of cancer,” said Richard Gaynor, M.D., senior vice president of product development and medical affairs for Lilly Oncology.

“We are pleased to offer ramucirumab as a new option in these treatment settings as we continue delivering on Lilly’s commitment to people living with lung and gastrointestinal cancers.”